atropine has been researched along with risperidone in 19 studies
Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
---|---|---|---|---|---|
26,711 | 1,259 | 1,697 | 6,924 | 1,505 | 2,477 |
Protein | Taxonomy | atropine (IC50) | risperidone (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (52.63) | 29.6817 |
2010's | 9 (47.37) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
de Alvarenga, KAF; de Rezende, VB; Romano-Silva, MA; Rosa, DV; Sacramento, EK; Souza, BR | 1 |
Haenen, GRMM; Vrolijk, M; Zhang, M | 1 |
1 review(s) available for atropine and risperidone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
18 other study(ies) available for atropine and risperidone
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Neuroleptics: necrotising enterocolitis.
Topics: Antipsychotic Agents; Atropine; Benzodiazepines; Clozapine; Drug Therapy, Combination; Enterocolitis, Necrotizing; France; Humans; Risperidone; Sulpiride | 2009 |
Effects of antipsychotics on intestinal motility in zebrafish larvae.
Topics: Animals; Antipsychotic Agents; Atropine; Clozapine; Drug Evaluation, Preclinical; Gastrointestinal Motility; Gastrointestinal Tract; Haloperidol; Larva; Muscarinic Antagonists; Risperidone; Zebrafish | 2017 |
The Screening of Anticholinergic Accumulation by Traditional Chinese Medicine.
Topics: Animals; Atropine; Cimetidine; Drugs, Chinese Herbal; Ephedra sinica; Humans; Male; Medicine, Chinese Traditional; Muscarinic Antagonists; Pirenzepine; Rats; Rats, Inbred WKY; Receptors, Cholinergic; Risperidone; Theophylline | 2017 |